BlackRock Japan’s Actinium Pharmaceuticals ATNM Stock Holding History

BlackRock Japan’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-75	Closed	-$4K	–	1391
2015 Q3	$4K	Sell	75 -5	-6%	-$334	﹤0.01%	1222
2015 Q2	$6K	Buy	+80	New	+$6.83K	﹤0.01%	1298

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BlackRock Japan's ATNM Position: Q4 2015 in Review

BlackRock Japan sold out of Actinium Pharmaceuticals (ATNM) in Q4 2015, closing a stake of 75 shares — an estimated $4K sold.

BlackRock Japan first reported a position in ATNM in Q2 2015 and held it in 2 quarters. The position peaked at $6K in Q2 2015. 24 funds tracked by Wall St. Rank hold ATNM as of Q4 2015.

BlackRock Japan reported no remaining Actinium Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
BlackRock Japan sold 75 Actinium Pharmaceuticals shares in Q4 2015, an estimated $4K.
BlackRock Japan first reported a position in Actinium Pharmaceuticals in Q2 2015 and held it in 2 quarters.
BlackRock Japan's Actinium Pharmaceuticals position peaked at $6K in Q2 2015.
24 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2015.

Based on BlackRock Japan's 13F filing for Q4 2015, filed 11 Feb 2016.